Skip to content
10-K

Annual Report

VITRO BIOPHARMA, INC.

0001493152-26-006592

← back to feed
Filed
Feb 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 13, 2026 4.52M sh
Shares Diluted FY 2025 · Oct 31, 2025 4.46M sh
Shares Diluted FY 2025 · Oct 31, 2024 4.46M sh
Capex FY 2025 · Oct 31, 2025 $5.17K
Operating Cash Flow FY 2025 · Oct 31, 2025 −$2.54M
Operating Cash Flow FY 2025 · Oct 31, 2024 −$3.24M
Long Term Debt FY 2025 · Oct 31, 2025 $8.99M
Long Term Debt FY 2025 · Oct 31, 2024 $3.05M
Short Term Debt FY 2025 · Oct 31, 2025 $593.75K
Short Term Debt FY 2025 · Oct 31, 2024 $5.2M
Stockholders Equity FY 2025 · Oct 31, 2025 −$16.33M
Stockholders Equity FY 2025 · Oct 31, 2024 −$9M
Stockholders Equity FY 2025 · Oct 31, 2023 −$1.09M
Current Liabilities FY 2025 · Oct 31, 2025 $5.68M
Current Liabilities restated FY 2025 · Oct 31, 2024 $10.06M
Total Liabilities FY 2025 · Oct 31, 2025 $21.26M
Total Liabilities restated FY 2025 · Oct 31, 2024 $14.23M
Current Assets FY 2025 · Oct 31, 2025 $862.1K
Current Assets FY 2025 · Oct 31, 2024 $975.75K
Total Assets FY 2025 · Oct 31, 2025 $4.93M
Total Assets restated FY 2025 · Oct 31, 2024 $5.22M
Eps Diluted FY 2025 · Oct 31, 2025 −$2.44
Eps Diluted FY 2025 · Oct 31, 2024 −$2.21
Eps Basic FY 2025 · Oct 31, 2025 −$2.44
Eps Basic FY 2025 · Oct 31, 2024 −$2.21
Sga Expense FY 2025 · Oct 31, 2025 $6.06M
Sga Expense FY 2025 · Oct 31, 2024 $6.62M
Rd Expense FY 2025 · Oct 31, 2025 $533.03K
Rd Expense FY 2025 · Oct 31, 2024 $618.27K
Net Income FY 2025 · Oct 31, 2025 −$10.85M
Net Income FY 2025 · Oct 31, 2024 −$9.87M
Operating Income FY 2025 · Oct 31, 2025 −$5.02M
Operating Income FY 2025 · Oct 31, 2024 −$9.15M
Gross Profit FY 2025 · Oct 31, 2025 $1.57M
Gross Profit FY 2025 · Oct 31, 2024 $1.43M
Cost Of Revenue FY 2025 · Oct 31, 2025 $483.34K
Cost Of Revenue FY 2025 · Oct 31, 2024 $426.19K
Revenue FY 2025 · Oct 31, 2025 $2.06M
Revenue FY 2025 · Oct 31, 2024 $1.86M